Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Weighing Their Options Merck rivals Eli Lilly and Novo Nordisk have so far dominated the GLP-1 weight-loss market with Zepbound and Ozempic, respectively
For example, AI can help develop nanocarriers that target infection-specific receptors, minimizing off-target effects
The study reinforces concerns already being raised by clinicians and people with lived experience of eating disorders namely that appetite-suppressing and weight-loss medications may intersect with eating disorder symptoms and recovery in complex ways, she said
Continue a leitura e saiba todos os detalhes
Free shipping from 60 Your order can always be tracked with Track & Trace
Drugs 2023;83(5):403-427
US$ 25.23
US$ 21.09
US$ 25.61
US$ 20.33
US$ 27.62
US$ 24.47
